What is Congenital Nephrotic Syndrome Finnish Type

Congenital Nephrotic Syndrome Finnish Type (CNF) is a rare, severe genetic kidney disorder characterized by massive protein loss in the urine (proteinuria) that begins shortly after birth or in utero. It is caused by mutations in the NPHS1 gene, which prevent the kidneys from effectively filtering blood, leading to significant swelling and fluid retention.

What causes Congenital Nephrotic Syndrome Finnish Type?

Congenital Nephrotic Syndrome Finnish Type is caused by mutations in the NPHS1 gene, which provides instructions for making a protein called nephrin. Nephrin is essential for the structure of the glomerular filtration barrier in the kidneys. When this protein is absent or non-functional, the kidneys cannot prevent proteins from leaking into the urine. This condition is inherited in an autosomal recessive pattern, meaning a child must inherit two copies of the mutated gene—one from each parent—to develop the disease.

Who is affected by Congenital Nephrotic Syndrome Finnish Type?

While Congenital Nephrotic Syndrome Finnish Type was first identified in Finland, where it occurs in approximately 1 in 8,200 births, cases have been diagnosed worldwide. The condition affects both males and females equally. Key clinical features often observed in infants with Congenital Nephrotic Syndrome Finnish Type include:

• Large placenta at birth (often weighing more than 25% of the infant's birth weight).


• Severe edema (swelling) due to the loss of albumin protein in the urine.


• Low blood protein levels (hypoalbuminemia) and high cholesterol (hyperlipidemia).


• Increased susceptibility to infections and blood clots in early infancy.

How is this condition different from other kidney diseases?

Unlike other forms of nephrotic syndrome that may respond to steroids or immunosuppressive medications, Congenital Nephrotic Syndrome Finnish Type is typically resistant to these treatments. The primary clinical management often involves aggressive nutritional support, albumin infusions, and eventually, kidney transplantation, which is the definitive treatment for Congenital Nephrotic Syndrome Finnish Type. Four members of our DiseaseMaps.org community are currently navigating these experiences and sharing their insights.

Next steps

• Consult with a pediatric nephrologist to discuss specialized management protocols.


• Meet with a clinical geneticist to review family history and inheritance patterns.


• Connect with the DiseaseMaps.org community to share experiences with other families affected by Congenital Nephrotic Syndrome Finnish Type.


• Research clinical trials or long-term registry studies through the NIH GARD portal.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Congenital nephrotic syndrome of Finnish type (ORPHA:657)


• NIH Genetic and Rare Diseases (GARD) Information Center: Congenital nephrotic syndrome, Finnish type


• OMIM (Online Mendelian Inheritance in Man): Nephrotic syndrome, congenital, Finnish type (Entry #256300)


• National Kidney Foundation: Pediatric Nephrotic Syndrome resources